Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Who May Be Eligible (Plain English)

Who May Qualify: - diagnosed by tissue sample (biopsy-confirmed) squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with diagnosed by tissue sample (biopsy-confirmed) squamous cell carcinoma of the head and neck. - Able to sign a Stanford IRB approved consent form Who Should NOT Join This Trial: - Refuse or unable to sign an IRB approved consent form. - Refuse to be contacted in the future for follow up. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck. * Able to sign a Stanford IRB approved consent form Exclusion criteria: * Refuse or unable to sign an IRB approved consent form. * Refuse to be contacted in the future for follow up.

Treatments Being Tested

PROCEDURE

Tumor biopsy

For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen

PROCEDURE

Phlebotomy

Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University

Locations (1)

Stanford University School of Medicine
Stanford, California, United States